By Fineline Cube 
GlaxoSmithKline (NYSE: GSK) announced today that the Chinese National Medical Products Administration (NMPA) has granted approval for Shingrix® (Recombinant Zoster Vaccine, CHO cell) to prevent shingles (herpes zoster) in adults aged 18 years and older who are at increased risk due to immunodeficiency or immunosuppression from disease or therapy, including autologous haematopoietic stem cell transplantation.
Key Facts
| Item | Detail |
|---|---|
| Vaccine | Shingrix® (recombinant subunit, glycoprotein E + AS01B adjuvant) |
| Approval | China NMPA for adults ≥ 18 yrs with immunocompromise |
| Indication | Prevention of herpes zoster (shingles) |
| Global Context | Approved worldwide for adults ≥ 50 yrs; expanding to younger high‑risk adults in China |
Why Shingrix Matters
- Non‑Live, Recombinant Platform – Eliminates risk of vaccine‑associated disease in immunocompromised patients.
- AS01B Adjuvant – Boosts immunogenicity, counteracting age‑related immune decline.
- Broad Coverage – Protects high‑risk groups, including transplant recipients and patients on immunosuppressive therapy.
Impact for China
China’s NMPA approval expands Shingrix’s reach to a critical segment of the population—immunocompromised adults who are most vulnerable to zoster reactivation. GSK will work with local partners to scale distribution and ensure timely access for eligible patients.
About GlaxoSmithKline
GlaxoSmithKline (GSK) is a global research‑driven pharmaceutical company focused on improving health through innovative medicines, vaccines, and consumer healthcare products. The company’s vaccine portfolio includes several life‑saving immunizations, with Shingrix® among its flagship products for viral disease prevention.-Fineline Info & Tech